Off The Bench: Some Action Letter Recipients Could See 2009 Action
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
At least four novel products that are currently benched - having gone through one review cycle and been taken out of the game by an FDA action letter - could rejoin the review fray in time to receive 2009 action goals
You may also be interested in...
AstraZeneca's MedImmune Comes Closer To Motavizumab Approval, And A Tight Grip On RSV Market
AstraZeneca's biologics unit MedImmune is continuing to solidify its domination of the market for products to prevent serious respiratory syncytial virus disease in high-risk infants with a formal reply to FDA's "complete response" letter for its investigational product motavizumab
Change Is Constant For Pneumococcal Vaccines: US CDC Prepares For Merck’s V116
As Merck’s 21-valent vaccine approaches its 17 June user fee goal, the US CDC’s vaccine committee is looking at new adult age-based recommendations and bracing for a full pipeline led by GSK’s 24-valent candidate.